Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk
Status:
Not yet recruiting
Trial end date:
2034-06-01
Target enrollment:
Participant gender:
Summary
Hormone therapy is recommended for five years in all patients with hormone receptor-positive
breast cancer, but there is no consensus on its duration in low-risk tumours and especially
in postmenopausal women. Adjuvant endocrine therapy (ET) is associated with substantial side
effects and long-term decreased quality of life.
Moreover, while it has been shown that ET provides a real benefit in reducing the relapse
rate over time, the deterioration in quality of life may also have a negative effect on
patient adherence to treatment. It is therefore important to offer treatment to women with
low-risk cancer less intensive treatment strategies. If recent trials tested longer durations
as compared to 5 years for high-risk cancers, older trials have tested shorter durations. The
5-year duration appeared at that time as the gold standard because of optimal benefit-risk
ratios of tamoxifen among high-risk patients. However shorter treatments of 2-3 years were
already associated with substantial benefits and may be enough for very low risk patients.